Where can researchers source third-party tested Tirzepatide (GLP-2 TZ)?

Midwest Peptide supplies research-grade Tirzepatide (GLP-2 TZ) with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Memorial Day: 15% off code MEMDAY15Memorial Day Sale — 15% off site-wide with code MEMDAY15

Free shipping on every orderFree shipping on every order

5% off with Zelle or Apple CashSave an extra 5% when you pay with Zelle or Apple Cash

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

GIP Receptor Research: Second Incretin | Midwest Peptide

Dual Incretin Agonist Body Composition Research in Animal ModelsPrev|Dual Incretin Receptor Activation: GLP-1 and GIP Combined MechanismNext

GIP Receptor Biology: The Second Incretin in Research

Q: Is Tirzepatide (GLP-2 TZ) approved for human use?

No. Tirzepatide (GLP-2 TZ) is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

GLP-2 TZ · Published April 9, 2026 · Updated May 18, 2026 · 9 min read

Quick Answer

GIP receptor research covers the structure, Gαs signaling, tissue distribution, and insulin-stimulating effects of glucose-dependent insulinotropic polypeptide. Studies examine pancreatic, adipose, and central GIP receptor biology and the contribution to integrated incretin pharmacology in research models. For research use only, not for human consumption.

GIP Receptor Biology: The Second Incretin in Research

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

What Is GIP?
The GIP Receptor
GIP Receptor Tissue Distribution
GIP Effects on Insulin Secretion
GIP Effects on Adipose Tissue
GIP and the Incretin Effect
GIP Receptor and the Class B GPCR Family
Open Research Questions
Conclusion
Related Research Articles
Explore Related Products
Frequently Asked Questions
Glossary

GIP receptor research provides essential context for understanding GLP-2 TZ as a dual GLP-1/GIP receptor agonist. The GIP (glucose dependent insulinotropic polypeptide) receptor is the second of the two main incretin receptors, and its biology has been the subject of substantial preclinical research that complements the broader literature on the GLP-1 receptor system. As the GIP receptor biology component of the GLP-2 TZ research cluster, this article reviews the published literature on GIP receptor structure, signaling, tissue distribution, and biological functions.

Frequently Asked Questions

What is Tirzepatide (GLP-2 TZ) in research contexts?

Tirzepatide (GLP-2 TZ) is a synthetic dual GLP-1/GIP receptor agonist with a 39-amino-acid sequence and a fatty-acid modification for extended half-life. It is studied in preclinical research for glucose regulation, food intake, and adipose tissue endpoints.

What is the structure of the GIP receptor?

The GIP receptor (GIPR) is a class B G protein-coupled receptor with seven transmembrane domains and a large extracellular N-terminal ligand-binding domain. It is structurally related to the GLP-1 receptor and similarly couples to Gs alpha to elevate cAMP.

Where is GIPR expressed and what does activation do?

GIPR is expressed in pancreatic beta cells, adipose tissue, brain (hypothalamus, hippocampus), bone, and other tissues. Activation enhances glucose-stimulated insulin secretion, modulates adipose lipid storage, and contributes to integrated incretin biology.

Is Tirzepatide (GLP-2 TZ) approved for human use?

Glossary

Key terms used in this article.

Dual Agonist: A pharmacological agent that simultaneously activates two distinct receptors with one molecule.
GIP: Glucose-dependent insulinotropic polypeptide, an incretin hormone secreted by intestinal K cells that potentiates insulin secretion.
GIP Receptor (GIPR): The class B G protein-coupled receptor for GIP, expressed in pancreatic islets, adipose tissue, and other peripheral tissues.
Lipidation: Covalent attachment of a fatty acid to a peptide to enable albumin binding and extend plasma half-life.
K Cell: An enteroendocrine cell type in the intestinal mucosa that secretes GIP in response to nutrient ingestion.
Beta Cell: The pancreatic islet cell type that synthesizes and secretes insulin and amylin in response to glucose.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. The peptides discussed in this article are intended exclusively for in vitro and preclinical research. They are not approved for human use, are not drugs, and should never be administered to humans or to animals outside of an authorized research protocol.

What Is GIP?

GIP (glucose dependent insulinotropic polypeptide) is a 42 amino acid peptide hormone produced by intestinal K cells in response to nutrient intake. It was originally identified for its ability to enhance glucose dependent insulin secretion, which is the basis for its name "glucose dependent insulinotropic polypeptide." GIP is one of the two main incretin hormones, alongside GLP-1, and together they account for most of the incretin effect on insulin secretion in research models.

GIP is released into systemic circulation following nutrient intake, particularly in response to glucose and fat in the intestine. Once in circulation, GIP reaches the pancreas and other target tissues where it acts on the GIP receptor to produce its biological effects. The GIP signaling pathway has been characterized through extensive research, providing a substantial preclinical evidence base on its biology.

The relationship between GIP and GLP-1 is one of the most important features of incretin research. Both hormones contribute to the incretin effect, but they have distinct cellular sources, distinct receptor systems, and somewhat different effects in various tissues. Understanding both hormones is essential for understanding integrated incretin biology and for interpreting research with dual agonist compounds like GLP-2 TZ.

The GIP Receptor

The GIP receptor is a class B G protein coupled receptor structurally related to the GLP-1 receptor and to other receptors in the secretin receptor family. The receptor was cloned in the early 1990s and has been characterized through subsequent research as the primary target for GIP signaling in research models.

Structurally, the GIP receptor follows the typical class B GPCR architecture with an extracellular N-terminal domain that contributes to ligand binding, a seven transmembrane helical bundle that contains the activation machinery, and intracellular loops that interact with G proteins and downstream signaling components. The structural similarities with the GLP-1 receptor are substantial and reflect the close evolutionary relationship between these two incretin receptors.

The signaling pathways downstream of GIP receptor activation involve coupling to the Gs alpha subunit, activation of adenylyl cyclase, increases in intracellular cyclic AMP, and downstream activation of protein kinase A. This canonical class B GPCR signaling cascade is shared with the GLP-1 receptor and explains many of the similarities in cellular effects between the two incretin receptors.

Beyond the canonical signaling, the GIP receptor also engages additional pathways including beta-arrestin signaling, modulation of intracellular calcium, and various other downstream effects that contribute to the integrated cellular response. The relative contributions of these different pathways depend on the cellular context.

GIP Receptor Tissue Distribution

The GIP receptor is expressed in multiple tissues throughout the body, with the most studied sites being pancreatic beta cells, adipose tissue, and various brain regions. The tissue distribution of the GIP receptor overlaps with but differs from that of the GLP-1 receptor, providing the basis for the complementary effects of GIP and GLP-1 in integrated incretin biology.

Pancreatic beta cells express the GIP receptor at high levels, where it mediates the incretin effect of GIP on glucose dependent insulin secretion. The GIP receptor on beta cells is one of the major sites of incretin signaling in research models.

Adipose tissue is one of the more interesting sites of GIP receptor expression because it provides a tissue-specific effect that is largely unique to GIP rather than shared with GLP-1. The GIP receptor on adipocytes contributes to effects on adipose tissue metabolism and gene expression in research models.

Brain regions including the hypothalamus express the GIP receptor and mediate central effects of GIP on feeding behavior and energy balance. The central GIP signaling complements the central effects of GLP-1 receptor activation.

Bone tissue is another site where GIP receptor expression has been characterized, with research on effects on bone biology and remodeling. This is one of the more distinctive aspects of GIP receptor research compared to other incretin receptors.

GIP Effects on Insulin Secretion

The most studied effect of GIP receptor signaling in research models is the enhancement of glucose dependent insulin secretion. Like GLP-1 receptor activation, GIP receptor activation amplifies insulin secretion in response to elevated glucose, with minimal effects when glucose levels are normal or low.

The mechanism of GIP effects on insulin secretion involves the canonical cyclic AMP/protein kinase A pathway in pancreatic beta cells. Cyclic AMP elevation amplifies the insulin secretory response that is initiated by glucose-stimulated changes in beta cell membrane potential and calcium influx. This amplification produces enhanced insulin release in response to glucose challenges.

The combined contribution of GIP and GLP-1 to insulin secretion is one of the foundational features of integrated incretin biology. Both hormones contribute to the overall incretin effect, and combined activation of both receptors produces enhanced insulin responses in research models that exceed activation of either alone.

GIP Effects on Adipose Tissue

The effects of GIP on adipose tissue are one of the more distinctive features of GIP biology compared to GLP-1. The GIP receptor on adipocytes mediates effects on lipid metabolism, on adipocyte gene expression, and on the broader adipose tissue response to nutrient signals.

Research on GIP effects on adipose tissue has characterized changes in lipogenic gene expression, in lipolysis, and in adipocyte differentiation in cell culture systems. Animal model studies have extended these findings to whole-organism contexts, characterizing how GIP receptor signaling affects adipose tissue mass and function in research animals.

The adipose tissue effects of GIP contribute to the body composition profile of dual GLP-1/GIP agonists, since these compounds engage GIP receptor activity that single GLP-1 receptor agonists do not. For more on the body composition effects of dual agonism, see our companion article on Dual incretin agonist body composition research in animal models.

GIP and the Incretin Effect

The incretin effect refers to the observation that oral glucose produces a larger insulin response than intravenous glucose at the same plasma glucose concentration. The difference reflects the contribution of incretin hormones (GIP and GLP-1) released by the intestine in response to oral glucose, which amplify the insulin response above what glucose alone would produce.

Both GIP and GLP-1 contribute to the incretin effect, with the relative contributions varying somewhat across research contexts and species. In healthy research animals, the incretin effect accounts for approximately 50-70% of the postprandial insulin response, illustrating the importance of incretin signaling in normal glucose regulation.

The contribution of GIP specifically to the incretin effect can be characterized using GIP receptor antagonists or GIP receptor knockout research models. These approaches have shown that GIP makes a substantial contribution to the overall incretin effect in research animals, particularly under conditions of normal glucose regulation.

The dual GLP-1/GIP agonist approach in research with compounds like GLP-2 TZ takes advantage of this combined incretin signaling by activating both receptors simultaneously, producing enhanced insulin responses compared to selective GLP-1 receptor agonists.

GIP Receptor and the Class B GPCR Family

The GIP receptor is part of the broader class B GPCR family that also includes the GLP-1 receptor, the GLP-2 receptor, the glucagon receptor, the secretin receptor, the GHRH receptor, the calcitonin receptor (which forms the amylin receptor complexes when associated with RAMPs), the parathyroid hormone receptors, and various other receptors that bind peptide hormone ligands.

The shared structural and functional features across class B GPCRs provide context for understanding individual receptors within the broader family. Many of the same signaling pathways and structural features are conserved across the family, even though the specific ligands and biological functions differ between receptors.

For more on the broader incretin and class B GPCR family research, see our companion article on GLOW Blend Scar Remodeling Research: Wound Healing and Fibrosis Animal Model Studies in the GLP-3 RT research cluster.

Open Research Questions

Several open research questions remain in the GIP receptor research literature. These include how the relative contributions of GIP and GLP-1 to integrated incretin effects vary across different research conditions, how GIP receptor signaling in adipose tissue affects metabolic outcomes, and how the structural details of GIP receptor activation captured by recent crystal structures inform the development of selective GIP receptor research tools. Each of these is a legitimate research opportunity for investigators studying class B GPCR pharmacology.

Conclusion

GIP receptor research provides essential context for understanding GLP-2 TZ as a dual GLP-1/GIP receptor agonist. The GIP receptor biology, including its tissue distribution, signaling pathways, and contributions to integrated incretin signaling, provides the foundation for understanding why dual incretin agonists produce effects that distinguish them from selective GLP-1 receptor agonists. For investigators using GLP-2 TZ 30mg as a research tool, the GIP receptor literature provides essential context for experimental design.

For more on the full GLP-2 TZ research cluster, see the pillar overview article and the supporting articles on each major topic.

GLP-2 TZ is supplied by Midwest Peptide for research use only and is not intended for human administration.

Explore more peer-reviewed research and laboratory guides from our science team:

All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.

GLOW 70mg, 99%+ purity, COA included
GLP-1 SM 20mg, 99%+ purity, COA included
GLP-2 TZ , 99%+ purity, COA included
GLP-3 RT, 99%+ purity, COA included

Browse All Research Peptides →

Age Verification

GIP Receptor Biology: The Second Incretin in Research

Frequently Asked Questions

What is Tirzepatide (GLP-2 TZ) in research contexts?

What is the structure of the GIP receptor?

Where is GIPR expressed and what does activation do?

Is Tirzepatide (GLP-2 TZ) approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

What Is GIP?

The GIP Receptor

GIP Receptor Tissue Distribution

GIP Effects on Insulin Secretion

GIP Effects on Adipose Tissue

GIP and the Incretin Effect

GIP Receptor and the Class B GPCR Family

Open Research Questions

Conclusion

Ready to Start Your Research?

Where can researchers source third-party tested Tirzepatide (GLP-2 TZ)?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?

Age Verification

GIP Receptor Biology: The Second Incretin in Research

Frequently Asked Questions

What is Tirzepatide (GLP-2 TZ) in research contexts?

What is the structure of the GIP receptor?

Where is GIPR expressed and what does activation do?

Is Tirzepatide (GLP-2 TZ) approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

What Is GIP?

The GIP Receptor

GIP Receptor Tissue Distribution

GIP Effects on Insulin Secretion

GIP Effects on Adipose Tissue

GIP and the Incretin Effect

GIP Receptor and the Class B GPCR Family

Open Research Questions

Conclusion

Related Research Articles

Explore Related Products

Ready to Start Your Research?

Where can researchers source third-party tested Tirzepatide (GLP-2 TZ)?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?